Hims & Hers Health (NYSE:HIMS) Trading 11.4% Higher – Time to Buy?

Hims & Hers Health, Inc. (NYSE:HIMS)’s share price traded up 11.4% on Monday . The stock traded as high as $29.69 and last traded at $29.8670. 10,285,276 shares traded hands during mid-day trading, a decline of 66% from the average session volume of 30,489,139 shares. The stock had previously closed at $26.82.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Barclays sees breakout potential for Hims & Hers as the Novo partnership and weight-loss offerings could drive stronger revenue and EBITDA growth in the second half of 2026. HIMS Stock Gained Nearly 6% On Wednesday — Barclays Sees Breakout Potential After Novo Partnership
• Positive Sentiment: Analysts are focused on an upcoming FDA peptide review that could serve as the next major growth catalyst for Hims & Hers. HIMS Stock Breaks Above $30 Ahead Of Upcoming FDA Peptide Review: Analysts Eye Next Growth Catalyst
• Positive Sentiment: Investor enthusiasm remains high around peptides and GLP-1 treatments, with some bullish commentary suggesting the market opportunity could be larger than current forecasts. Hims & Hers Stands to Get a Big Chunk of the $2.2B Peptides Market
• Neutral Sentiment: Insider selling disclosures from COO Michael Chi and employee Irene Becklund were made under pre-arranged 10b5-1 plans and were tied to tax withholding from equity vesting, which makes them less concerning than open-market insider selling.
• Neutral Sentiment: Market commentary highlighted Hims & Hers’ strong recent share performance and ongoing momentum, but did not add a new fundamental catalyst. Hims & Hers Health, Inc. (HIMS) Ascends While Market Falls: Some Facts to Note
• Negative Sentiment: The insider sales, while routine, may still create some short-term caution for investors if the stock’s valuation remains stretched.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. TD Cowen lowered their target price on Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a report on Friday, March 27th. Morgan Stanley lowered their target price on Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 24th. Wall Street Zen lowered Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Evercore set a $24.00 price objective on Hims & Hers Health in a research report on Tuesday, February 24th. Finally, Bank of America dropped their price objective on Hims & Hers Health from $28.00 to $25.00 and set a “neutral” rating for the company in a research report on Tuesday, May 26th. Four equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health has an average rating of “Hold” and a consensus price target of $29.37.

Hims & Hers Health Trading Up 1.6%

The business has a 50-day moving average of $25.87 and a 200 day moving average of $26.65. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. The stock has a market cap of $7.40 billion, a PE ratio of -355.22, a PEG ratio of 56.60 and a beta of 2.37.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The business had revenue of $608.10 million during the quarter, compared to analyst estimates of $616.84 million. During the same period in the previous year, the business posted $0.20 earnings per share. The firm’s quarterly revenue was up 3.8% on a year-over-year basis. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.04 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 7,950 shares of the firm’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $23.64, for a total transaction of $187,938.00. Following the sale, the chief financial officer directly owned 262,954 shares in the company, valued at approximately $6,216,232.56. This trade represents a 2.93% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Irene Becklund sold 4,490 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total value of $141,435.00. Following the sale, the insider owned 6,790 shares in the company, valued at approximately $213,885. The trade was a 39.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders sold 131,267 shares of company stock worth $3,628,628. Insiders own 11.76% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Hims & Hers Health by 7.2% during the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after buying an additional 1,407,651 shares during the period. Capital World Investors raised its holdings in shares of Hims & Hers Health by 1.2% during the 3rd quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock valued at $1,065,399,000 after buying an additional 223,892 shares during the period. Farallon Capital Management LLC raised its holdings in shares of Hims & Hers Health by 30.8% during the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after buying an additional 2,533,271 shares during the period. State Street Corp increased its holdings in Hims & Hers Health by 1.8% during the 4th quarter. State Street Corp now owns 7,305,525 shares of the company’s stock worth $237,210,000 after purchasing an additional 132,311 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Hims & Hers Health by 12.4% during the 4th quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock worth $183,485,000 after purchasing an additional 608,950 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.